

ASX Announcement

Analytica enters into DOCA and completes Asset Sale

Analytica Ltd (Subject to Deed of Company Arrangement) (ASX:ALT) (**Analytica**), announces that following the appointment of Administrators on 13 June 2023, a second meeting of creditors was held on 20 July 2023 where creditors approved a deed of company arrangement (**DOCA**) proposed by Stratos MedTech Pty Ltd ACN 668 737 022 and Stratos MedTech Holdings Pty Ltd ACN 669 147 862 (**Stratos Companies**).

DOCA

The DOCA was entered into yesterday, 24 July 2023. Key terms of the DOCA include:

- the Stratos Companies contribute \$290,000 to a Deed Fund (**Stratos Contribution**) to pay out the costs of the Administrator and participating creditors' claims – the amount has been received by the Administration;
- Creditors' claims (including shareholder loans totalling c\$3.1 million from entities associated with Dr Michael Monsour) are extinguished upon payment of the Stratos Contribution (subject to claims under the DOCA against the Deed Fund and on liquidation if the DOCA is terminated and Analytica is put into liquidation);
- Analytica and the Stratos Companies enter into an asset sale agreement for the sale of Analytica's business and assets (**Asset Sale Agreement**); and
- control of Analytica passes back to the directors.

Asset Sale

Analytica has entered into and completed the Asset Sale Agreement in accordance with the DOCA under which the Stratos Companies agreed to buy and Analytica agreed to sell its business and assets (**Assets**) and shares in Pericoach Pty Ltd ACN 602 999 860 and Invion Limited ACN 094 730 417 (**Shares**). The Assets and Shares were sold on an 'as is where is' basis with no warranties.

De-listing and winding up

The Directors now presently intend to seek shareholders' approval for the de-listing and winding up of Analytica by a solvent liquidation following completion of the DOCA which is expected within approximately 2 months.

This announcement has been authorised by the Board.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com